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Background: For patients with brain metastases, systemic disease burden has his-
torically been accepted as a major determinant of overall survival (OS). However, less 
research has focused on specific history and physical findings made by clinicians and 
how such findings pertain to patient outcomes at a given time point. The aim of this study 
is to determine how the initial clinical assessment of patients with brain metastases, as 
part of the history and physical at the time of consultation, correlates to patient prognosis.
Methods: We evaluated a prospective, multi-institutional database of 1523 brain metas-
tases in 507 patients who were treated with radiosurgery (Gamma Knife or CyberKnife) 
from 2001 to 2014. Relevant history of present illness (HPI) and past medical history 
(PMH) variables included comorbidities, Eastern Cooperative Oncology Group (ECOG) 
performance status, and seizure history. Physical exam findings included a sensory 
exam, motor exam, and cognitive function. Univariate and multivariate Cox regression 
analyses were used to identify predictors of OS.
results: Two hundred ninety-four patients were included in the final analysis with a median 
OS of 10.8 months (95% CI, 7.8–13.7 months). On univariate analysis, significant HPI 
predictors of OS included age, primary diagnosis, performance status, extracranial metas-
tases, systemic disease status, and history of surgery. Significant predictors of OS from the 
PMH included cardiac, vascular, and infectious comorbidities. On a physical exam, findings 
consistent with cognitive deficits were predictive of worse OS. However, motor deficits or 
changes in vision were not predictive of worse OS. In the multivariate Cox regression analy-
sis, predictors of worse OS were primary diagnosis (p = 0.002), ECOG performance status 
(OR 1.73, p < 0.001), and presence of extracranial metastases (OR 1.22, p = 0.009).
conclusion: Neurological deficits and systemic comorbidities noted at presentation are 
not associated with worse overall prognosis for patients with brain metastases under-
going radiosurgery. When encountering new patients with brain metastases, the most 
informative patient-related characteristics that determine prognosis remain performance 
status, primary diagnosis, and extent of extracranial disease.
Keywords: history and physical, radiosurgery, brain metastases, performance status, neurological deficits, 
prognosis, comorbidity
March 2016 | Volume 6 | Article 402
Paydar et al. Prognostic Factors for Stereotactic Radiosurgery
Frontiers in Oncology | www.frontiersin.org
inTrODUcTiOn
For patients with brain metastases undergoing radiation treatment, 
patient-specific variables such as performance status and extracra-
nial disease burden are commonly used to prognosticate overall 
survival (OS). Numerous therapies exist to treat such systemic 
and intracranial disease, including chemotherapy, radiation, and 
supportive care; therefore, patient selection must be a priority 
before initiating treatment because each therapy has unique risks 
and benefits. Several prognostic indices have been developed for 
patients with brain metastases to improve patient selection for and 
to predict outcomes after treatment.
In the seminal predictive models of patient outcomes, baseline 
neurological function at presentation has inconsistently been 
included as a potential prognostic variable. In an analysis of 
patients included in three Radiation Therapy Oncology Group 
(RTOG) studies undergoing whole brain fractionated radio-
therapy, neurological function was included as a potential prog-
nostic factor in the regression analysis (1). Although neurological 
function was not one of the variables that ultimately defined 
prognostic groups on recursive partitioning analysis (RPA), it 
was a statistically significant prognostic variable on univariate 
analysis. Importantly, the RTOG RPA, which enrolled patients as 
early as 1979, did not include patients treated with radiosurgery, 
and, therefore, its results may not be generalizable to patients with 
intracranial metastases treated with radiosurgery alone. Other 
prognostic indices published in the more modern era were based 
on analyses of patients treated with either whole brain radiation 
therapy (WBRT) (2, 3), stereotactic radiosurgery (4, 5), or either 
one of these modalities (6–8). These indices did not evaluate 
neurological function as a potential prognostic indicator; hence, 
it was not included in the resulting scoring systems.
Most key prognostic indices include a measure of perfor-
mance status, such as Karnofsky performance status (KPS) score 
or Eastern Cooperative Oncology Group (ECOG) score. These 
scores are determined by the examining clinician, attempt to 
quantify the general well-being of patients, and are often inde-
pendent of the underlying pathology. A recent study reported 
that a neurological cause of a low KPS score was associated with 
a statistically significant improved prognosis in patients who 
undergo radiosurgery (9). Moreover, another published nomo-
gram provides individual estimates of neurological death after 
salvage stereotactic radiosurgery for patients who have failed 
prior WBRT after adjusting for their competing risk of death 
from non-neurological causes (10). These findings underscore 
the potential prognostic value of neurological deficits elicited 
on a physical exam in determining outcomes for patients with 
brain metastases who undergo treatment with radiosurgery.
The goal of our study was to determine whether neurological 
deficits noted prior to radiation treatment predicted for worse 
outcomes in patients treated with stereotactic radiosurgery for 
brain metastases. To the best of our knowledge, this is the only 
multi-institutional review examining the relevance of the neuro-
logical examination when determining a patient’s prognosis in 
the setting of radiosurgery. Other patient-related and treatment-
related variables were also assessed to delineate potential prog-
nostic variables from this patient population.
MaTerials anD MeThODs
Participant selection and study Design
We performed a retrospective evaluation of a prospectively 
collected, multicenter database of 1523 brain metastases in 507 
patients who were treated with radiosurgery (Gamma Knife or 
CyberKnife) between 2001 and 2014. Institutional Review Board 
approval for the accumulation of clinical data for the purpose of 
this study was obtained from The University of North Carolina 
at Chapel Hill, New York University, and Georgetown University 
Hospital. From the 507 patients, 213 patients were excluded 
because they had received prior surgery or intracranial radiation 
or had been lost to follow-up. The remaining 294 patients with 
newly diagnosed brain metastases, biopsy-confirmed primary 
or metastatic disease, and no prior treatment with intracranial 
radiation were included in the final analysis (Figure 1).
Baseline Variables and Treatment
The patient variables included gender, age, primary diagnosis/
histology, total intracranial tumor volume, systemic disease 
burden, and systemic disease control. Systemic disease burden 
was determined by positron emission tomography (PET)/CT 
and was quantified by the number of major organ systems with 
active metastatic lesion. Systemic disease control was defined as 
improved or stable disease over serial PET/CT. Radiosurgical 
treatment planning was carried out as previously described 
(11), and final fractionation and dosage was determined based 
on the gross tumor volume (GTV) and proximity to critical 
structures. Patients could receive further treatment including 
WBRT, surgical resection, or repeat radiosurgery if they failed 
initial therapy or developed symptomatic mass effect. These 
treatments were administered at the discretion of the treating 
physicians.
Outcomes assessment
Radiographic control of treated intracranial lesions was assessed 
by serial magnetic resonance imaging (MRI) obtained as a 
part of routine clinical follow-up. Patients were imaged every 
2–3  months after radiosurgery at the discretion of the treat-
ing radiation oncologist and neurosurgeon. For patients with 
multiple intracranial lesions at the time of radiosurgery or who 
developed new lesions distal to the site of treatment, local control 
(LC) was defined as control of the specific lesions treated with 
radiosurgery. OS was calculated from the last day of treatment 
until the date of death. All patients were monitored clinically 
for radiosurgery-associated toxicity throughout the length of 
follow-up, and all such toxicities observed were recorded and 
scored utilizing the Common Toxicity Criteria for Adverse Events 
version 4.0 (CTCAE v.4).
statistical analysis
Between-group differences were assessed using the log-rank test 
or Chi-square test within each of the study cohorts for categorical 
data. Ordinal variables were assessed utilizing gamma (a type of 
rank correlation). Cumulative event rates for individual variables 
were calculated according to the Kaplan–Meier method with dif-
ferences in survival curves assessed using the log-rank method. 
507 paents entered in database
294 paents 
eligible for analysis
Medical history 
analysis and feature 
selecon (best Cox 
model by backward LR)
Medical PMH analysis 
and feature selecon 
(best Cox model by 
backward LR)
Physical exam analysis 
and feature selecon 
(best Cox model by 
backward LR)
213 paents were excluded due 
to: incomplete comorbidity list, 
insufficient follow-up, incomplete 
neurological exam at inial 
presentaon, or lost to follow-up
Mulvariate survival model
FigUre 1 | Flow chart representing the patient selection process and analytic plan.
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Multivariate Cox proportional-hazards regression models were 
constructed for the overall study population using variables 
found to be significant (α =  0.05) on univariate analysis. All 
reported ranges are interquartile ranges (IQR) defined as the 
range between the 25th percentile and the 75th percentile. All 
reported p values are two sided, with an alpha of 0.05. All data 
management and analyses were conducted using SPSS 21.0 (IBM, 
Inc., Armonk, NY, USA) as well as the open source SCikit-learn 
library in Python.
resUlTs
Patient and Treatment characteristics
Two hundred ninety-four patients with brain metastases were 
included in the final analysis. The median age at diagnosis was 
63, and 57% were male. The most common primary diagnosis 
was non-small cell lung cancer (NSCLC) (52%). The majority of 
treated patients (83%) had an ECOG performance status of 0 or 
1 and low extra-cranial disease burden (63% with 0–1 sites of 
disease). However, extracranial disease was uncontrolled in the 
majority of patients (67%). The median number of intracranial 
metastases was 2, and the median tumor volume was 1.7 mm3. 
Thirty-six percent of patients presented with a neurological com-
plaint, the most common of which was a motor deficit (15%). For 
the remainder of the patients, brain metastases were noted on 
routine surveillance imaging (64%). Patients were treated with a 
median dose of 19 Gy (IQR, 18–20 Gy) in one (91%), two (8%), or 
three (1%) fractions. Specifics of baseline patient characteristics 
are shown in Tables 1 and 2.
Overall survival and local control
For the entire patient population, the median OS was 10.8 months 
(95% CI, 7.8–13.7 months). With respect to primary diagnosis, 
patients with breast cancer demonstrated the best median 
OS (23.4  months; 95% CI, 15.7–31.2  months), followed by 
renal cell carcinoma (12.1  months; 95% CI, 0.1–24.2  months), 
NSCLC (9.9 months; 95% CI, 8.1–11.7 months), and melanoma 
(6.7 months; 95% CI, 5.4–8.0 months) (Figures 2A,B). Freedom 
from local recurrence was 94% over the course of the study with 
a median freedom from local recurrence of 41 months (95% CI, 
37.6–44.7 months).
Modeling initial Presentation survival 
Predictors
In the univariate Cox regression analysis, key predictors of worse 
OS from the history of present illness (HPI), past medical his-
tory (PMH), and neurological exam were older age (OR 1.03, 
p =  0.001) and site of primary disease (p <  0.001) (Table  3). 
Specifically, compared to NSCLC, melanoma had a slightly 
increased risk (OR 1.63, p = 0.022), while breast carcinoma (OR 
0.62, p = 0.084) and RCC (OR 0.45, p = 0.077) had decreased risk. 
Other predictors of worse OS were ECOG performance status 
(OR 1.55, p <  0.001); presence of extracranial metastases (OR 
1.20, p = 0.005); systemic disease burden (OR 2.36, p < 0.001); 
a PMH of cardiac disease (OR 2.06, p = 0.005), vascular disease 
(OR 1.87, p = 0.004), or infectious disease (OR 3.53, p = 0.042); 
and a neurological exam demonstrating cognitive decline (OR 
2.03, p =  0.007). The presence of any neurological deficit was 
also a statistically significant predictor of worse OS on univariate 
TaBle 2 | Baseline neurological examination and symptoms.
Patient characteristic
Seizures – no. (%) 21 (7)
Motor deficits – no. (%) 45 (15)
Cognitive deficits – no. (%) 28 (10)
Vision loss – no. (%) 13 (4)
TaBle 1 | Baseline characteristics of patients and treatments with newly 
diagnosed brain metastases.
Patient characteristic
Gender – no. (%)
Male 127 (57)
Female 167 (43)
Age – years (IQR) 63 (55–70)
Total intracranial tumor volume – mm3 (IQR) 1.7 (0.7–3.7)
Primary diagnosis – no. (%)
NSCLC 152 (52)
Breast cancer – all types 63 (22)
Melanoma 64 (22)
Renal cell carcinoma 15 (5)
ECOG – no. (%)
0 93 (32)
1 151 (51)
2 39 (13)
3+ 11 (4)
Extracranial metastatic burden – no. sites (%)
0 63 (21)
1 124 (42)
2 52 (18)
3 27 (9)
4 21 (7)
5+ 7 (2)
Systemic disease status – no. (%)
Controlled 96 (33)
Uncontrolled 198 (67)
Number of metastases – median no. (IQR) 2 (1–4)
Whole brain radiation therapy – no. (%)a 52 (23)
Cranial surgery – no. (%)a 62 (21)
Isodose % (IQR) 50 (50–80)
Isocenters – median (IQR) 3 (1–6)
Dose – median (IQR) 19 (18–20)
Fractions – no. (%)
1 267 (91)
2 25 (8)
3 2 (1)
aTreatment received after SRS.
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analysis (OR 1.48, p = 0.043). Predictors of improved OS were 
presence of intracranial metastases only (OR 0.89, p = 0.526) and 
history of cranial surgery after radiosurgery (OR 0.59, p = 0.025). 
In the multivariate Cox regression analysis, predictors of worse 
OS were primary diagnosis (p =  0.002), ECOG performance 
status (OR 1.73, p < 0.001), and presence of extracranial metas-
tases (OR 1.22, p = 0.009) (Figures 3A,B; Table 4). Neurological 
deficits assessed individually or all together were not statistically 
significant predictors of OS (OR = 1.32 [0.84–2.06], p = 0.23 for 
deficits assessed together).
Toxicity
All patients were able to complete radiation treatment without 
interruption. Patients were also able to tolerate treatment with 
minimal toxicity. Specifically, 5% of patients experienced acute 
grade 1–2 toxicity. Two patients (0.7%) experienced intratumoral 
hemorrhages post-radiosurgery, and two patients (0.7%) had new 
seizures. The most common treatment-related side effects were 
headaches, nausea, and alopecia; these were medically managed, 
often with corticosteroid therapy.
DiscUssiOn
Brain metastases are the most common intracranial malignancy (12, 
13), with an incidence of 20–40% based on autopsy data (14–16). 
The median survival generally ranges from 2 to 14 months, depend-
ing on prognostic factors, primary diagnosis, and tumor burden 
(1, 6, 17, 18). However, as many patients continue to live beyond 
the historical time range, WBRT is increasingly reserved for pallia-
tion in patients with large intracranial disease burden. More focal 
neurosurgical and stereotactic approaches are often the treatment 
of choice for patients with few (generally one to three) brain metas-
tases or patients expected to be long-term survivors. How do we 
capture these survivors and guide them to the appropriate therapy?
In order to guide medical decision-making for patients with 
varied presentations and treatment options, several prognostic 
indices specifically addressing patients with brain metastases have 
been published in the literature. The most extensively utilized 
and validated prognostic system is the RTOG RPA, followed by 
the graded prognostic assessment (GPA) and diagnosis-specific 
graded prognostic assessment (DS-GPA) (1, 6, 7). However, 
significant heterogeneity in terms of patient populations, treat-
ment approaches, patient factors assessed, statistical approaches, 
and number of prognostic groups has been observed between 
the various prognostic indices (19), demonstrating that such 
indices require ongoing improvement and optimization. The 
information obtained from the history and physical exam stands 
as the foundation for most of these indices as well as the clini-
cian’s assessment of the patient’s cognition and prognosis. What 
information obtained from it, if any, is important for improving 
these indices?
In the RTOG RPA scoring system, univariate analysis of all 
covariates included neurological signs and symptoms as well as 
neurological function; however, these factors did not emerge as 
prognostic indicators in the overall analysis (1). Importantly, 
this index was based on patients undergoing conventionally 
fractionated whole brain radiotherapy (with one trial including 
a conventionally fractionated boost to GTV). In an attempt to 
diminish subjectivity and thereby improve reproducibility in 
these indices, the GPA and DS-GPA – which did include patients 
treated with radiosurgery  –  eliminated neurological function 
and physical exam findings in the regression tree analysis and 
only included easily quantifiable characteristics, such as age, KPS, 
number of CNS metastases, presence or absence of extracranial 
metastases, and primary diagnosis (6, 7). Ultimately, little data 
exist on the utility of the presenting neurological symptoms and 
signs noted on physical exam as prognostic indicators in patients 
treated with radiosurgery for brain metastases.
TaBle 3 | Predictors of overall survival from hPi, PMh, and neurological 
exam on univariate analysis.
Patient characteristic Or (95% ci) p-Value
history of present illness
Seizures 1.57 (0.82–3.0) 0.170
Age 1.03 (1.01–1.04) 0.001
Primary diagnosisa – <0.001
 Breast carcinoma 0.62 (0.36–1.07) 0.084
 Melanoma 1.63 (1.07–2.46) 0.022
 RCC 0.45 (0.19–1.09) 0.077
ECOG 1.55 (1.24–1.94) <0.001
Extracranial metastasesb 1.20 (1.06–1.37) 0.005
Intracranial metastasesc 0.89 (0.63–1.27) 0.526
Systemic disease status 2.36 (1.59–3.52) <0.001
History of cranial surgery 0.59 (0.37–0.94) 0.025
History of WBRT 0.86 (0.58–1.24) 0.425
Past medical history
Cardiac 2.06 (1.25–3.41) 0.005
Vascular 1.87 (1.23–2.83) 0.004
Infectious 3.53 (1.05–11.9) 0.042
neurological exam
Motor deficit 1.12 (0.70–2.01) 0.515
Vision loss 1.36 (0.60–3.10) 0.459
Any neurological deficit 1.48 (1.01–2.15) 0.043
aOdds ratio is compared to a baseline of NSCLC.
bOR is for every additional independent system with active metastatic disease.
cMedian number for series was two metastases, treated as over/under two metastases 
or oligometastases versus multiple metastases.
FigUre 2 | (a) Kaplan–Meier curves representing overall survival for all patients and (B) separated with respect to primary diagnosis.
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Our study included data from a multicenter prospectively col-
lected database of 294 patients from three institutions treated with 
radiosurgery for brain metastases. In the multivariate analysis of 
standard elements of patient history and physical findings, neuro-
logical deficits noted on physical exam were not predictive of OS. 
In concordance with the previously published prognostic indices, 
historical factors predictive of OS in our study were primary diag-
nosis, ECOG performance status, and presence of extracranial 
metastases. Also consistent with previous reports, the presence 
of renal and breast histology conferred a better prognosis when 
compared to NSCLC or melanoma in our regression analysis.
The median survival of our patients was 10.8  months, and 
our patients were observed to maintain prolonged freedom from 
local recurrence (median 41  months). Additionally, patients 
completed SRS with minimal acute and chronic toxicity. These 
excellent results demonstrate that despite the importance of per-
formance status on determining overall prognosis, worse perfor-
mance status specifically due to neurologic deficits should likely be 
initially overlooked. Radiosurgery should continue to be offered 
to patients with intracranial metastases, especially if a patient’s 
performance status was normal prior to and compromised after 
presentation with a brain metastasis. The optimal treatment 
decision should be determined in a multidisciplinary setting 
where all treatment options are considered for each individual 
patient in the context of his or her presenting signs, symptoms, 
performance status, previous treatments, current disease status, 
and available options (20).
TaBle 4 | Multivariate model of overall survival.
Patient characteristic Or (95% ci) p-Value
History of present illness
Primary diagnosisa – 0.002
ECOG 1.73 (1.34–2.21) <0.001
Extracranial disease burdenb 1.22 (1.05–1.42) 0.009
Past Medical History – N/A
Neurologic exam – N/A
aOdds ratio varies depending upon specific diagnosis/histology with 
Melanoma > NSCLC > RCC > Breast.
bOR is for every additional independent system with active metastatic disease.
FigUre 3 | cox-hazard regression results separated by (a) ecOg performance status and (B) extracranial disease status demonstrating the 
expected effect of worsening performance status and systemic disease on overall predicted survival.
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The ideal treatment paradigm for patients with brain metas-
tases also continues to be optimized as new studies delineate 
the role of radiosurgery alone as initial therapy. Historically, the 
optimal treatment strategy for this patient population has varied 
significantly between treating centers and has been primarily 
based on the treating physician and patient preference. Recent 
randomized clinical trials have established the utility of radio-
surgery alone without WBRT for patients with few (one to four) 
brain metastases (21–23). A recently published individual patient 
data meta-analysis of these three trials demonstrated an improve-
ment in OS without an increased risk of distant brain failure for 
patients <50 years of age treated with radiosurgery alone (24). 
Similarly, recent results from the RTOG 0617/Alliance (NCCTG 
N0574) show that in patients with one to three brain metastases, 
when compared to WBRT plus radiosurgery, radiosurgery alone 
confers similar OS without a decline in cognitive function (25). 
The conclusion from these prospectively conducted studies is 
that for patients with low intracranial disease burden, young 
age, good performance status, and close follow-up, radiosurgery 
alone may be an adequate initial treatment strategy. Further stud-
ies will further optimize the treatment decision-making process 
based on prognostic and predictive factors reported here and 
elsewhere.
study limitations
This was a retrospective study, and as such, there may be an 
inherent selection bias. Despite the maximal means undertaken 
to reduce or eliminate the effect of bias, the authors acknowl-
edge that it is impossible to fully safeguard a retrospective study 
from such sources of analytical bias. This study was multi-
institutional, and as such, our cohort of patients was evaluated 
by multiple physicians who may determine performance status 
and neurological deficits differently from each other. However, 
this is not a unique limitation to our study because even 
single-institution reports include patients treated by multiple 
physicians.
Conceptually, this study aims to describe a new patient 
presenting as a consultation with new brain metastases and 
possible neurological deficits. However, not all patients present 
to practicing radiation oncologists and neurosurgeons with this 
scenario, and such examples include an unknown primary or a 
patient who has already received intracranial therapy multiple 
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times. Furthermore, our analysis is broad, and it is possible that 
the significance of the PMH (comorbidities) varies for specific 
histologic subtypes of cancer. For example, in patients with 
hormone positive breast carcinoma, PMH may be a significant 
predictor of clinical decision making and outcomes.
cOnclUsiOn
Neurological deficits noted at presentation are not associated 
with worse overall prognosis for patients with brain metastases 
undergoing radiosurgery. When encountering new patients with 
brain metastases, the most informative patient-related charac-
teristics that determine prognosis remain performance status 
 (independent of recent neurological compromise), primary diag-
nosis, and presence of extracranial metastases.
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